Sylvia is an experienced biotech industry professional with over ten years of experience in the sector. Prior to joining the T1D fund, she was a Principal on the investment team at Omega Funds, where she focused on early stage investments and company creation across various therapeutic areas including neurology, immunology and rare diseases. She also served as a Board observer for Vanqua Bio, Aerium Therapeutics and Rectify Pharma.

Prior to Omega Funds, Sylvia spent almost 7 years at Ra Pharmaceuticals, a peptide drug discovery company focused on rare diseases associated with complement dysregulation. At Ra, she was involved in the early development of the company’s discovery platform, as well as developing preclinical and translational models for first-in-human studies of its lead product, Zilucoplan, which was recently approved in various countries for generalized myasthenia gravis (gMG). She also provided scientific leadership for multiple discovery programs within the company’s internal pipeline and in collaboration with Merck.

Sylvia earned her Ph.D in Biochemistry Summa Cum Laude from the University Pierre-and-Marie-Curie in Paris, France, while being a full-time visiting fellow in the Department of Genetics at Harvard University where she worked in synthetic biology. She holds an M.S. from Pierre-and-Marie-Curie University in Paris, France and a B.S. in Biochemistry from Joseph-Fourier University in Grenoble, France.

Chief Investment Officer, Chevy Chase Trust

 

Amy Raskin is a pioneer in global thematic investing and widely respected as a bold thought leader. As the Chief Investment Officer of Chevy Chase Trust since February 1, 2014, she has propelled the firm to a leadership position in thematic investing, a small, but rapidly growing approach to investing that MSCI  added to its universe of style categories last year.

 

Under her leadership, Chevy Chase Trust has outperformed its global benchmark in each of the last seven years, by an average of 5.5% after fees; it is in the top decile of managers for the last 3-, 5- and 10 years. Amy is also a monthly guest on CNBC.

 

Prior to joining Chevy Chase Trust, Amy was Senior Vice President at AllianceBernstein in New York, serving as Director of Research for Thematic Portfolios, Director of Research on Strategic Change, head of U.S. & Global Growth Equity Research and Chief Investment Officer of AB Venture Capital Fund. The Research on Strategic Change team published in-depth research papers on a wide range of thematic investment topics, such as broadband, China, hybrid vehicles, climate change and molecular medicine.

Earlier, she worked as an investment banker at Lehman Brothers and as a research analyst at Donaldson, Lufkin & Jenrette.

 

Amy graduated from the University of Pennsylvania’s School of Engineering and Applied Science with a Bachelor of Science in Engineering and is an active, long-term member of the Penn Association of Alumnae and the Trustees’ Council of Penn Women (TCPW). She currently serves as Co-Chair of the TCPW Development Committee, and sits on the School of Engineering and Applied Science’s Technical Advisory Board. Her most recent commitment is to funding and supporting research on Type 1 diabetes, which her younger son was diagnosed with in mid-2020.